# Bernard Majoie

> Bernard Majoie is a seed investor at Fournier-Majoie (Brussels) backing Biotechnology and Medical. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Fournier-Majoie](https://shizune.co/investors/profile/fournier-majoie)
- Location: Brussels, Belgium
- Total investments: 6
- Last investment: Jul 2021
- Lead investor: 33%
- Last updated: Aug 2026

Bernard Majoie is a seed investor at Fournier-Majoie in Brussels focused on Biotechnology and Medical. Bernard Majoie - President @ Fournier-Majoie

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.3M–$2.7M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 50% |
| Medical | 2 | 33% |
| Health Care | 1 | 17% |
| Life Science | 1 | 17% |
| Neuroscience | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 33% |
| Pre-Seed | 1 | 17% |
| Series A | 1 | 17% |
| Series B | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 2 | 33% |
| Belgium | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AgenT | AgenT develops the first blood diagnosis to detect Alzheimer's years before the onset of the irreversible symptoms. | $2.7M | Seed | Jul 01, 2021 |  |
| PEP-Therapy | PEP-Therapy is a biotechnology company developing first-in-class peptides as targeted therapies for severe diseases, with an initial focus on cancer. PEP-Therapy develops Cell Penetrating and Interfering Peptides (CP&IP) for the intracellular delivery of targeted therapies. These active compounds penetrate cells and block relevantintracellular protein-protein interactions, thus inhibiting key pathological mechanisms. | $3.3M | Series A | Apr 22, 2021 |  |
| AgenT | AgenT develops the first blood diagnosis to detect Alzheimer's years before the onset of the irreversible symptoms. | $1.2M | Pre-Seed | Jan 31, 2020 |  |
| reMYND | Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models.They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugscurrently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept. | $13.2M | Series B | Dec 18, 2018 |  |
| PEP-Therapy | PEP-Therapy is a biotechnology company developing first-in-class peptides as targeted therapies for severe diseases, with an initial focus on cancer. PEP-Therapy develops Cell Penetrating and Interfering Peptides (CP&IP) for the intracellular delivery of targeted therapies. These active compounds penetrate cells and block relevantintracellular protein-protein interactions, thus inhibiting key pathological mechanisms. | $1.3M | Seed | Nov 16, 2017 |  |
| PEP-Therapy | PEP-Therapy is a biotechnology company developing first-in-class peptides as targeted therapies for severe diseases, with an initial focus on cancer. PEP-Therapy develops Cell Penetrating and Interfering Peptides (CP&IP) for the intracellular delivery of targeted therapies. These active compounds penetrate cells and block relevantintracellular protein-protein interactions, thus inhibiting key pathological mechanisms. | $1.4M | Seed | Apr 27, 2015 |  |

6 of 6 investments shown.

## Co-investors
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 2 deals together
- [BNP Paribas Fortis](https://shizune.co/investors/profile/bnp-paribas-fortis) — VC Fund, 1 deal together
- [Business Angels des Grandes Ecoles](https://shizune.co/investors/profile/business-angels-des-grandes-ecoles) — VC Fund, 1 deal together
- [Doorway Capital](https://shizune.co/investors/profile/doorway-capital) — VC Fund, 1 deal together
- [Gemma Frisius Fund](https://shizune.co/investors/profile/gemma-frisius-fund) — VC Fund, 1 deal together
- [Italian Angels for Growth](https://shizune.co/investors/profile/italian-angels-for-growth) — VC Fund, 1 deal together

## About Fournier-Majoie

VC Fund · Brussels, Belgium

Fournier-Majoie Foundation is a non-profit organization whose mission is to identify, support and guide promising researchers.

1 contacts available at Fournier-Majoie.

| Name | Title | Profile |
| --- | --- | --- |
| Bernard Majoie | President | https://shizune.co/investors/profile/bernard-majoie |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [Biotech Angel Investors](https://shizune.co/investors/biotech-angel-investors)
- [Biotechnology Angel Investors](https://shizune.co/investors/biotechnology-angel-investors)
- [Biotechnology Angel Investors in Europe](https://shizune.co/investors/biotechnology-angel-investors-europe)
- [Biotechnology Investors in France](https://shizune.co/investors/biotechnology-investors-france)
- [Biotechnology Angel Investors in France](https://shizune.co/investors/biotechnology-angel-investors-france)
- [Biotech Angel Investors in Europe](https://shizune.co/investors/biotech-angel-investors-europe)

## FAQ

### What does Bernard Majoie invest in?

Bernard Majoie invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Pre-Seed stage. Most of the 6 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Bernard Majoie's check size?

Bernard Majoie typically joins rounds of $1.3M–$2.7M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bernard Majoie participates in.

### When did Bernard Majoie last invest?

The most recent investment recorded for Bernard Majoie closed in Jul 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co